2022 is shaping up to be another spectacular year for Pfizer

JuliusGoldsmith

This time last year Pfizer projected $15 billion in Covid vaccine sales in 2021. Actual sales ($36.8 billion) came in 2.45 times higher, making the Pfizer Covid vaccine the top-selling pharmaceutical product ever in a single year (by a huge margin). Pfizer only projects out revenues once they have an agreement or contract.
Based on existing deals, Pfizer is currently projecting $22 billion in sales for Paxlovid in 2022. Assuming we get a repeat of what happened last year with the vaccine, we are potentially looking at $54 billion in Paxlovid revenue in 2022. Pfizer plans to manufacture 120 million courses of Paxlovid this year. Assuming $54 billion in Paxlovid sales, that comes to $450 per course. The current contracts with the US govt pay $530 each for 20 million courses to be delivered by Sep 2022.
Whatever Pfizer makes from Paxlovid is on top of the $32 billion in sales projected from the Covid vaccine in 2022.
Bottom line: 2022 is shaping up to be another spectacular year for Pfizer. Paxlovid has the potential to break the single-year sales record set last year by the Pfizer Covid vaccine.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

KLok
2022-02-16
KLok
hopefully....

Leave a comment

2

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":9095259156,"tweetId":"9095259156","gmtCreate":1644935340158,"gmtModify":1676533976973,"author":{"id":9000000000000525,"authorId":9000000000000525,"authorIdStr":"9000000000000525","name":"JuliusGoldsmith","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"2022 is shaping up to be another spectacular year for Pfizer","extraTitle":"","html":"<html><head></head><body><p>This time last year Pfizer projected $15 billion in Covid vaccine sales in 2021. Actual sales ($36.8 billion) came in 2.45 times higher, making the Pfizer Covid vaccine the top-selling pharmaceutical product ever in a single year (by a huge margin). Pfizer only projects out revenues once they have an agreement or contract.<br>Based on existing deals, Pfizer is currently projecting $22 billion in sales for Paxlovid in 2022. Assuming we get a repeat of what happened last year with the vaccine, we are potentially looking at $54 billion in Paxlovid revenue in 2022. Pfizer plans to manufacture 120 million courses of Paxlovid this year. Assuming $54 billion in Paxlovid sales, that comes to $450 per course. The current contracts with the US govt pay $530 each for 20 million courses to be delivered by Sep 2022.<br>Whatever Pfizer makes from Paxlovid is on top of the $32 billion in sales projected from the Covid vaccine in 2022.<br>Bottom line: 2022 is shaping up to be another spectacular year for Pfizer. Paxlovid has the potential to break the single-year sales record set last year by the Pfizer Covid vaccine.</p> <p><a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a></p></body></html>","htmlText":"<html><head></head><body><p>This time last year Pfizer projected $15 billion in Covid vaccine sales in 2021. Actual sales ($36.8 billion) came in 2.45 times higher, making the Pfizer Covid vaccine the top-selling pharmaceutical product ever in a single year (by a huge margin). Pfizer only projects out revenues once they have an agreement or contract.<br>Based on existing deals, Pfizer is currently projecting $22 billion in sales for Paxlovid in 2022. Assuming we get a repeat of what happened last year with the vaccine, we are potentially looking at $54 billion in Paxlovid revenue in 2022. Pfizer plans to manufacture 120 million courses of Paxlovid this year. Assuming $54 billion in Paxlovid sales, that comes to $450 per course. The current contracts with the US govt pay $530 each for 20 million courses to be delivered by Sep 2022.<br>Whatever Pfizer makes from Paxlovid is on top of the $32 billion in sales projected from the Covid vaccine in 2022.<br>Bottom line: 2022 is shaping up to be another spectacular year for Pfizer. Paxlovid has the potential to break the single-year sales record set last year by the Pfizer Covid vaccine.</p> <p><a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a></p></body></html>","text":"This time last year Pfizer projected $15 billion in Covid vaccine sales in 2021. Actual sales ($36.8 billion) came in 2.45 times higher, making the Pfizer Covid vaccine the top-selling pharmaceutical product ever in a single year (by a huge margin). Pfizer only projects out revenues once they have an agreement or contract. Based on existing deals, Pfizer is currently projecting $22 billion in sales for Paxlovid in 2022. Assuming we get a repeat of what happened last year with the vaccine, we are potentially looking at $54 billion in Paxlovid revenue in 2022. Pfizer plans to manufacture 120 million courses of Paxlovid this year. Assuming $54 billion in Paxlovid sales, that comes to $450 per course. The current contracts with the US govt pay $530 each for 20 million courses to be delivered by Sep 2022. Whatever Pfizer makes from Paxlovid is on top of the $32 billion in sales projected from the Covid vaccine in 2022. Bottom line: 2022 is shaping up to be another spectacular year for Pfizer. Paxlovid has the potential to break the single-year sales record set last year by the Pfizer Covid vaccine. $Pfizer(PFE)$","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9095259156","repostId":0,"isVote":1,"tweetType":1,"viewCount":327,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":935,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":100556806,"gmtCreate":1645016201162,"gmtModify":1663243885541,"authorId":3582450584533032,"author":{"id":3582450584533032,"authorId":3582450584533032,"name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9095259156,"type":1,"supId":0,"prevId":0,"content":"hopefully....","text":"hopefully....","html":"hopefully....","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/9095259156"}